All terms in DRUGBANK

Label Id Description
Betula pendula tar oil DB11361 [Betula pendula tar oil is an essential oil found in the buds of the plant with the same name. The origin plant, also known as the European white or silver birch, grows mainly in the northern hemisphere. This oil is usually obtained by using both hydrodistillation and micro-distillation[A33154] and it is conformed mainly by [DB11143] and [DB11359].[T219] The utilization of this product started during the second world war in the Sovietic Union.[L2870] Betula pendula tar oil has been approved for its utilization in over-the-counter product combinations by Health Canada.[L1113] By the FDA, it is considered under the substances approved to be added to the food.[L2862] Under the EMA, betula pendula tar oil is approved under the category of herbal medicines for human use.[L2865]]
Chlorophetanol DB11368 [Chlorophetanol is an agent known to have antifungal activities.]
Gusperimus DB12692 [Gusperimus has been used in trials studying the treatment of Lupus Nephritis, Wegeners Granulomatosis, and Wegener's Granulomatosis.]
Cefroxadine DB11367 [Cefroxadine is an orally available cephalosporin antibiotic. As part of its drug class, it shares structural properties to [cefalexin] as well as its activity spectrum. It was used in Italy but has since been withdrawn.]
Ritanserin DB12693 [Ritanserin has been used in trials studying the treatment of Cocaine-Related Disorders.]
Roquinimex DB11366 [Roquinimex is a derivative of quinoline that presents immunostimulant properties. Its effects are suggested to increase the activity of NK cells and macrophage cytotoxicity. Additionally, roquinimex is known to inhibit angiogenesis and to decrease the synthesis of TNF alpha.]
CE-326597 DB12694 [CE-326,597 has been used in trials studying the treatment of Obesity.]
Phenethyl Isothiocyanate DB12695 [Phenethyl Isothiocyanate has been used in trials studying the prevention and treatment of Leukemia, Lung Cancer, Tobacco Use Disorder, and Lymphoproliferative Disorders.]
Sennosides DB11365 [Sennosides (also known as senna glycoside or senna) is a medication used to treat constipation[FDA Label][L771] and empty the large intestine before surgery. The medication is taken by mouth or via the rectum[FDA Label]. It typically begins working in minutes when given by rectum and within twelve hours when given by mouth[FDA Label]. It is a weaker laxative than bisacodyl or castor oil[A177092]. Sennoside A, one of the sennosides present in the laxative medication, has recently proven effective in inhibiting the ribonuclease H (RNase H) activity of human immunodeficiency virus (HIV) reverse transcriptase [A19231].]
LY-2584702 DB12690 [LY2584702 has been used in trials studying the treatment of Cancer, Advanced Cancer, Renal Cell Carcinoma, Metastases, Neoplasm, and Neuroendocrine Tumors, among others.]
UK-432097 DB12691 [UK-432,097 has been used in trials studying the treatment of Pulmonary Disease, Chronic Obstructive.]
Efinaconazole DB09040 [Efinaconazole is a 14 alpha-demethylase inhibitor indicated in the treatment of fungal infection of the nail, known as onychomycosis. It was approved for use in Canada and the USA in 2014 and is marketed by Valeant Pharmaceuticals North America LLC under the name Jublia.]
Lactobacillus plantarum DB11360 [*Lactobacillus plantarum* is a member of Lactobacillus, or lactic acid bacteria, that it is widely used in the food industry as a microbial starter and probiotic microorganism. It is considered to be one of versatile species that carry out fermentative and metabolic processes, while exhibiting an antagonistic activity against pathogenic and spoilage microorganisms. *L. plantarum* produces different antimicrobial agents such as organic acids, hydrogen peroxide, diacetyl, bacteriocins, and antimicrobial peptides [A27208].]
Tedizolid phosphate DB09042 [Tedizolid Phosphate is an oxazolidinone-class antibiotic prodrug indicated in adults for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible isolates of several Gram-positive bacteria. Following administration via oral or intravenous route, tedizolid phosphate prodrug is converted by plasma phosphatases to its active moiety, [tedizolid]. The active metabolite of tedizolid binds to the 50S bacterial ribosomal subunit, inhibiting protein synthesis and causing its bacteriostatic effects. Tedizolid is an effective and potent alternative to linezolid for the treatment of patients with Gram-positive ABSSSI due to MRSA or MSSA. Increased potency allows for once daily dosing with reduced total dosages, improving the side effect profile of this drug. Of note, the minimum inhibitory concentrations of tedizolid appear to be largely unaffected by the chloramphenicol-florfenicol resistance (cfr) gene, which has been implicated in a number of published linezolid-resistant organism outbreaks.]
Tavaborole DB09041 [Tavaborale is a novel, boron-based topical antifungal medication for the treatment of onychomycosis, a fungal infection of the nail and nail bed due to *Trichophyton rubrum* or *Trichophyton mentagrophytes* infection. Tavaborole functions by inhibiting Leucyl-tRNA synthetase, or LeuRS, an essential fungal enzyme required for protein synthesis and for the catalysis of ATP-dependent ligation of L-leucine to tRNA(Leu).]
Albiglutide DB09043 [Albiglutide is a glucagon-like peptide-1 agonist (GLP-1) biologic drug indicated in the treatment of type 2 diabetes. It is marketed under the brands Eperzan and Tanzeum by GSK (GlaxoSmithKline). It is a dipeptidyl peptidase-4-resistant glucagon-like peptide-1 dimer fused to human albumin. Albiglutide was approved on April 15, 2014 by the FDA.]
Metreleptin DB09046 [Metreleptin, a recombinant analog of the human hormone leptin, is an orphan drug used to treat complications of leptin deficiency in people with congenital or acquired lipodystrophy. Affecting less than 500 people worldwide, lipodystrophy is characterized by a lack of adipose tissue, fat deposition in the muscles and liver, and metabolic complications such as hypertriglyceridemia, insulin resistance, diabetes mellitus, and fatty liver disease. These metabolic abnormalities are often aggravated by excessive food intake, which is further aggravated by leptin deficiency, a protein secreted by adipose tissue. Administration of Metreleptin results in improvement of metabolic symptoms including improvements in insulin resistance, reduced HbA1c and fasting glucose, reduced triglycerides, and reductions in food intake. Metreleptin is produced in E. coli and differs from native human leptin by the addition of a methionine residue at its amino terminus. It is administered as a once daily subcutaneous injection. On Feb. 24, 2014, Metreleptin was approved by the FDA for the treatment of complications of leptin deficiency, in addition to diet, in patients with congenital generalized or acquired generalized lipodystrophy. Metreleptin is marketed under the brand Myalept® by Aegerion Pharmaceuticals, Inc.]
Dulaglutide DB09045 [Dulaglutide is a novel glucagon-like peptide-1 agonist (GLP-1) biologic drug consisting of a dipeptidyl peptidase-IV-protected GLP-1 analogue covalently linked to a human IgG4-Fc heavy chain by a small peptide linker. Dulaglutide is indicated in the treatment of type 2 diabetes and can be used once a week. It was approved by the FDA in September 2014. Dulaglutide is manufactured and marketed by Eli Lily under the brand Trulicity™. It is not known if dulaglutide can increase the risk of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2, and is thus not recommended for use in populations with a personal or family history of these conditions.]
Netupitant DB09048 [Netupitant is an antiemitic drug approved by the FDA in October 2014 for use in combination with palonosetron for the prevention of acute and delayed vomiting and nausea associated with cancer chemotherapy including highly emetogenic chemotherapy. Netupitant is a neurokinin 1 receptor antagonist. The combination drug is marketed by Eisai Inc. and Helsinn Therapeutics (U.S.) Inc. under the brand Akynzeo.]
Finafloxacin DB09047 [Finafloxacin is a fluoroquinolone antibiotic indicated in the treatment of acute otitis externa (swimmer's ear) caused by the bacteria Pseudomonas aeruginosa and Staphylococcus aureus. Finafloxacin is marketed by Novartis under the brand Xtoro™, and was approved by the FDA in December 2014. ]